|
 |
TargretinThis page contains recent news articles, when available, and an overview of Targretin but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Targretin (when available) Bexarotene is a member of a subclass of retinoids that selectively activate retinoid X receptors (RXRs). These retinoid receptors have biologic activity distinct from that of retinoic acid receptors (RARs). Bexarotene is indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. Bexarotene selectively binds and activates retinoid X receptor subtypes (RXRa, RXRb, RXRg). RXRs can form heterodimers with various receptor partners such as retinoic acid receptors (RARs), vitamin Dy receptor, thyroid receptor, and peroxisome proliferator activator receptors (PPARs). Once activated, these receptors function as transcription factors that regulate the expression of genes that control cellular differentiation and proliferation. Bexarotene inhibits the growth in vitro of some tumor cell lines of hematopoietic and squamous cell origin. It also induces tumor regression in vivo in some animal models. For the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy Mechanism Of Action: The exact mechanism of action of bexarotene in the treatment of cutaneous T-cell lymphoma (CTCL) is unknown. News Articles on Bexarotene Local biotech firm wins OK on cancer drug - Nov 6, 2009 There are already three drugs on the market to treat CTCL, a form of non-Hodgkin's lymphoma: Ontak and Targretin, made by Eisai Inc. of Woodcliff Lake, NJ, ... Boston Globe Allos Therapeutics, Inc., Q3 2009 Earnings Call Transcript - Nov 3, 2009 The second trial is a randomized trial comparing FOLOTYN in combination with systemic Bexarotene, or Targretin, versus systemic Targretin alone in patients ... Seeking Alpha (blog) FDA Approves Drug Treatment for Rare Cancer - Nov 9, 2009 Previous approvals for CTCL included Zolinza (vorinostat), Ontak (denileukin difitox), and Targretin (bexarotene). Istodax was evaluated based on two ... FDA.gov Transcript Of Live Chat With Doctors - Oct 28, 2009 I am being treated with a gel called targretin. I was wondering if I should have a biopsy of my lymphnodes or some blood tests to see if this cancer has ... WFSB FDA Approves New Drug For Rare Cancer Cutaneous T-Cell Lymphoma - Nov 12, 2009 The other three are Zolinza (vorinostat), Ontak (denileukin difitox), and Targretin (bexarotene). The approval was granted on the evidence of two clinical ... Medical News Today New Management Hires for Burnham Aimed at Accelerating Commercialization Efforts - Oct 22, 2009 Burnham's pipeline includes three drugs that have already won FDA approval — heart attack medicines Integrilin and Aggrastat, and the cancer drug Targretin. ... GenomeWeb Daily News US FDA approves Istodax to treat rare form of cancer - Nov 11, 2009 Previous approvals for CTCL included Zolinza (vorinostat), Ontak (denileukin difitox), and Targretin (bexarotene). Istodax is marketed by Cambridge, ... pharmabiz.com Ligand Says Targretin Didn't Meet Endpoints in Phase II Studies - Mar 28, 2005 By Jeff Ward. March 28 (Bloomberg) -- Ligand Pharmaceuticals Inc. said Targretin, a lung cancer drug, didn't meet endpoints of improved overall survival and ... Bloomberg Targretin Fails to Meet Primary or Secondary Endpoints in Pivotal... - Mar 28, 2005 SAN DIEGO -- Ligand Pharmaceuticals Incorporated (Nasdaq:LGND) announced today that its two pivotal Phase III studies of Targretin(R) (bexarotene) capsules ... Free with registration - Business Wire - AccessMyLibrary.com Eisai Pays $205 Million for Four Ligand Cancer Drugs - Sep 8, 2006 It gives Eisai global rights to ONTAK and Targretin capsules, both of which are used to ... The agreement also covers rights to a gel version of Targretin, ... Bloomberg Ligand's Targretin Fails To Improve Survival In NSCLC - Mar 29, 2005 By Jennifer Boggs. Ligand Pharmaceuticals Inc.'s cancer drug Targretin missed its primary endpoints in two pivotal trials evaluating the drug in front-line ... BioWorld Online - BioWorld Online Cephalon Buys Drug Firm Zeneus - Dec 6, 2005 Through the takeover, Cephalon will get Myocet, a chemotherapy agent used for late-stage breast cancer, Targretin, a treatment for cutaneous T-cell lymphoma ... TheStreet.com - TheStreet.com (subscription) … REPLACING Investigators Present Detailed Targretin Lung Cancer... - May 16, 2005 Detailed reports of the results of Ligand Pharmaceuticals Incorporated (Nasdaq:LGNDE) two pivotal Phase III studies of Targretin(R) (bexarotene) capsules in ... RedOrbit New Data on Lung Cancer Trials with Targretin(R) is Presented at... - Jun 5, 2006 Ligand Pharmaceuticals Incorporated (Pink Sheets:LGND) (the "Company" or "Ligand") -- Results of retrospective analysis in large trials in first line NSCLC ... Genetic Engineering News - Genetic Engineering News (press release) Investigators Present Targretin(R) Data at World Lung Cancer … - Jul 5, 2005 Results of Ligand Pharmaceuticals Incorporated (Nasdaq:LGNDE) two pivotal Phase III studies (SPIRIT I & SPIRIT II) of Targretin(R) (bexarotene) capsules in ... RedOrbit Article: T-Cell activation key to targretin gel efficacy: the... - Apr 1, 2006 T-Cell activation key to targretin gel efficacy: the rexinoid is showing positive data in early-phase studies in several hard-to-manage dermatoses. Pay-Per-View - Skin & Allergy News - HighBeam Research … to settle patent interference on Targretin; Ligand strengthens... - Mar 14, 2005 The company believes the settlement strengthens Ligand's intellectual property position for bexarotene, the active ingredient in the Targretin products. ... Free with registration - Asia Africa Intelligence Wire - AccessMyLibrary.com Ligand Pharmaceuticals and the SALK Institute Enter Settlement … - Sep 5, 2008 ...the parties have resolved all disputes that have arisen between them including SALK's primary claim in arbitration relating to the sale of Targretin(R) ... Genetic Engineering News - Genetic Engineering News (press release) Ligand Pharmaceuticals, Inc., San Diego, Oct. 23 (DDMAC).(HUMAN … - Nov 1, 2006 The promotional piece also included claims for Ligand's Targretin (bexarotene). ... Targretin at a dose of 300 mg/m2/day is likely to increase her ... $4.95 - Warning Letter Bulletin - ECNext Targretin: endpoints missed in NSCLC trials.(non-small cell lung... - Apr 4, 2005 USA-based drugmaker Ligand Pharmaceuticals saw its shares plunge 28.5% to close at $5.88 on March 28, as investors' confidence waned on the news that two ... $4.95 - Pharma Marketletter - ECNext Eisai Announces Completion of Acquisition of Four Oncology-Related … - Oct 26, 2006 In the agreement, Eisai Co., Ltd. and Eisai Inc. obtained exclusive global rights to ONTAK(R) (denileukin diftitox), Targretin(R) (bexarotene) capsules, ... Free with registration - PR Newswire - AccessMyLibrary.com Targretin May Breathe Life into Ligand - Jan 17, 2005 Shares of Ligand may rise after results are released for Phase III trials of its lung cancer drug – Targretin, writes First Albany Capital. ... Subscription - Barron's Online - Dow Jones & Company INVESTIGATORS PRESENT TARGRETIN DATA AT WORLD LUNG … - Jul 7, 2005 Results of Ligand Pharmaceuticals' two pivotal Phase III studies (SPIRIT I & SPIRIT II) of Targretin (bexarotene) capsules in front-line combination therapy ... Pay-Per-View - FDAnews Drug Pipeline Alert - Factiva, from Dow Jones Phase II randomized bilateral comparison of topical targretin gel 1%... - Jan 1, 2005 The rationale for the use of bexarotene in alopecia areata comes from the drugs' immunomodulatory effects. It has been shown to be effective in inflammatory ... Free with registration - Journal of Drugs in Dermatology - AccessMyLibrary.com RECENTE INFORMATIE NOVEMBER 2007 - Nov 8, 2007 Bexaroteen (Targretin®) is een antitumoraal middel van de familie van de retinoïden (beschikbaar sinds november 2007). Bexaroteen wordt langs orale weg ... Belgisch centrum voor farmacotherapeutis... Cancer Therapy; New lung cancer research presented at ASCO - Jun 21, 2005 This is the first study to evaluate Targretin monotherapy in this patient population. The study completed accrual with 153 patients enrolled at 36 sites of ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Competitors by Product Report - Jun 16, 2007 Eisai Co., Ltd (ADR) (ESALY) Products:. Ontak (Denileukin Diftitox); Targretin Capsules (Bexarotene); Targretin Gel (Bexarotene) ... $75.00 - Revere Reports - Revere Competitors by Product Report - Dec 13, 2008 Eisai Co., Ltd (ADR) (ESALY) Products:. Ontak (Denileukin Diftitox); Targretin Capsules (Bexarotene); Targretin Gel (Bexarotene) ... $75.00 - Revere - Alacra Store Competitors by Product Report - Aug 2, 2008 Eisai Co., Ltd (ADR) (ESALY) Products:. Ontak (Denileukin Diftitox); Targretin Capsules (Bexarotene); Targretin Gel (Bexarotene) ... $75.00 - Revere - Alacra Store Ligand Announces Financial Results for First Quarter of Fiscal 2006. - May 15, 2006 Sales of Targretin capsules increased to $5.0 million for the three months ended March 31, 2006 compared to $4.0 million for the same 2005 period. ... Free with registration - Business Wire - AccessMyLibrary.com Gesundheits-Forum - Community - Gesundheit - FOCUS Online - Sep 8, 2007 ...in der klinik wurde ich dann mit targretin und puva behandelt. ... das targretin macht die ersten tage kopfschmerzen. gibt sich aber. ... focus.de Novel Targeted Agents Under Investigation for Non-Small Cell Lung … - May 13, 2005 Targretin is a novel, multi-targeted synthetic retinoid analogue, which selectively ... Targretin has demonstrated promising activity in advanced NSCLC when ... Cancer Consultants Merger and Acquisition Scenario - Apr 28, 2007 E5555; Ontak (Denileukin Diftitox); Targretin Capsules (Bexarotene) ... Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1% and Panretin ... $250.00 - Revere Reports - Revere Ligand Pharmaceuticals Inc. - Company Snapshot - AlacraStore.com - Nov 4, 2008 The major trademarks of the Group's are Ligand(R), ONTAK, Panretin, Targretin, and AVINZA. The four oncology products marketed in the United States are ... Pay-Per-View - co - Alacra Store Annales de Biologie Clinique - Jan 13, 2006 Le Targretin ® est maintenu avec une prise en charge des effets indésirables : fénofibrate ... Le médicament responsable est le Targretin ® (bexarotène). ... john-libbey-eurotext.fr Merger and Acquisition Scenario - May 19, 2007 E5555; Ontak (Denileukin Diftitox); Targretin Capsules (Bexarotene) ... Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1% and Panretin ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - May 19, 2007 E5555; Ontak (Denileukin Diftitox); Targretin Capsules (Bexarotene) ... Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1% and Panretin ... $250.00 - Revere Reports - Revere Morning Updates for Monday, August 14,2006 - While One Company … - Aug 14, 2006 Ligand Pharmaceuticals also markets Panretin gel and Targretin capsules in Europe. The company also has various products in clinical development, ... Free with registration - M2 Presswire - AccessMyLibrary.com Patents; Pharmaceutical company agrees to settle patent interference ... - Apr 11, 2005 The European Commission granted marketing authorization for Targretin capsules in ... Targretin is in continuing clinical trials in front-line, second-line, ... Pay-Per-View - Cancer Gene Therapy Week - Factiva, from Dow Jones Merger and Acquisition Scenario - Jun 16, 2007 E5555; Ontak (Denileukin Diftitox); Targretin Capsules (Bexarotene) ... Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1% and Panretin ... $250.00 - Revere Reports - Revere Morning Updates for Friday, August 11,2006 - As One Company … - Aug 11, 2006 Ligand Pharmaceuticals also markets Panretin gel and Targretin capsules in Europe. The company also has various products in clinical development, ... Free with registration - M2 Presswire - AccessMyLibrary.com Patents; Pharmaceutical company agrees to settle patent interference ... - Apr 14, 2005 The European Commission granted marketing authorization for Targretin capsules in ... Targretin is in continuing clinical trials in front-line, second-line, ... Pay-Per-View - Gene Therapy Weekly - Factiva, from Dow Jones Merger and Acquisition Scenario - Apr 7, 2007 E5555; Ontak (Denileukin Diftitox); Targretin Capsules (Bexarotene) ... Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1% and Panretin ... $250.00 - Revere Reports - Revere GIGM, TARO, VEGF, IGII, LGND, PPTI have been added to naked short … - Mar 21, 2006 Ligand Pharmaceuticals also markets Panretin gel and Targretin capsules in Europe. Further, the company has various products in clinical development, ... $4.95 - M2 Presswire - ECNext Press Release: Morning Updates for Friday, August 11,2006 - As One … - Aug 11, 2006 Ligand Pharmaceuticals also markets Panretin gel and Targretin capsules in Europe. The company also has various products in clinical development, ... Pay-Per-View - M2 Presswire - HighBeam Research Article: This lotion relieved; SEVERE DERMATITIS.(News) - Coventry … - Oct 6, 2007 Article: Ligand's Targretin Gel Shows Promise for Chronic Severe Hand ... ... Three patients in the Targretin gel monotherapy arm had a moderate-to-severe ... Pay-Per-View - Coventry Evening Telegraph - HighBeam Research Press Release: Bellwether Report.com is Scouting Ligand … - Sep 11, 2006 The sale includes Ligand's four marketed oncology drugs -- Ontak, Targretin capsules, Targretin gel and Panretin gel. Read all of this article with a FREE ... Pay-Per-View - M2 Presswire - HighBeam Research Competitors by Product Report - Dec 13, 2008 Eisai Co., Ltd (ADR) (ESALY) Products:. E6201 (Multikinase Inhibitor); Ontak (Denileukin Diftitox); Targretin Capsules (Bexarotene) ... $75.00 - Revere Reports - Revere Highlights of rising and falling US stocks - MarketWatch - Jan 14, 2005 The results of trials for Ligand's lung cancer drug Targretin are expected in late March. Should the drug be approved the stock would be expected to rise ... MarketWatch High Clinical Response Rate with Multimodality Immunomodulatory … - Aug 1, 2007 Article: Targretin[R] gel achieves 86% response rate in ... Dermatology Nursing; August 1, 2002 ; 579 words ...More than 85% of patients with early-stage ... Pay-Per-View - Dermatology Nursing - HighBeam Research Stockioi watch list for: Tuesday, May 16, 2006 IPRE, XTHN, XOHO,... - May 17, 2006 The major trademarks, trade names and service marks of the Group include Ligand(R), ONTAK, Panretin, Targretin, and AVINZA. The four oncology products ... $4.95 - M2 Presswire - ECNext Merger and Acquisition Scenario - Jan 26, 2008 Buyer (Total: 23). Fragmin (Dalteparin Sodium); E5555 (Thrombin Receptor Agonist); Targretin Gel (Bexarotene); Targretin Capsules (Bexarotene) ... $250.00 - Revere Reports - Revere Eisai buys 4 cancer drugs from Ligand Pharma. - Sep 18, 2006 ...for $205 M. Ontak (denileukin diftitox), Targretin capsules and Targretin gel (bexarotene) are designed for the treatment of cutaneous T lymphomas. ... Pay-Per-View - Chimie Pharma Hebdo - Factiva, from Dow Jones Eisai gains recognition as 'human health care company'. - Apr 28, 2008 Eisai obtained exclusive rights for Ontak, Targretin capsules, Targretin gel and Panretin from Ligand. Eisai also enjoys success by following what the ... $9.94 - Chain Drug Review - Alacra Store Competitors by Product Report - Apr 12, 2008 Eisai Co., Ltd (ADR) (ESALY) Products:. Ontak (Denileukin Diftitox); Targretin Capsules (Bexarotene); Targretin Gel (Bexarotene) ... $75.00 - Revere Reports - Revere Ligand says restatement of earnings is possible - Mar 18, 2005 The First Albany analyst noted that results from Ligand's Phase 3 study of its drug Targretin to treat lung cancer are expected soon, and good news there ... San Diego Union - Tribune - San Diego Union Tribune Rates climb on short-term bills - Mar 15, 2005 Targretin is approved by the US Food and Drug Administration to treat cutaneous t-cell lymphoma. The drug is being tested in clinical trials as a treatment ... San Diego Union - Tribune - San Diego Union Tribune Merger and Acquisition Scenario - Jan 26, 2008 Buyer (Total: 23). Fragmin (Dalteparin Sodium); E5555 (Thrombin Receptor Agonist); Targretin Gel (Bexarotene); Targretin Capsules (Bexarotene) ... $250.00 - Revere Reports - Revere 试验è?¯ç‰©ç–—æ•ˆæ¬ ä½³Ligandé‡?è·Œ24% - Mar 29, 2005 Ligand表示，虽然对上述试验的结果感到失望，但自己将继ç»ä»Žäº‹å°†Targretinå?šä¸ºæ··å?ˆ 化疗的第二ä½?和第三ä½?è?¯ç‰©çš„试验，治疗那些将Targretinå?šä¸ºä¸»è?¯çš„æ··å?ˆåŒ–疗未å?–得良好 ... 新浪网 Competitors by Product Report - Mar 29, 2008 E2007 (AMPA Receptor Antagonist); MGi Pharma AKR-501 (Thrombopoietin Mimetic); Ontak (Denileukin Diftitox); Targretin Capsules (Bexarotene); Targretin Gel ... $75.00 - Revere Reports - Revere Article: Unigen Pharmaceuticals hires Director of Clinical Research.(... - Mar 1, 2006 Article: Ligand Presents at AACR: Targretin Causes Regression of . ... Targretin in Human Clinical Trials In November 1998, Ligand launched Phase II human ... Pay-Per-View - Pharmaceutical Processing - HighBeam Research Competitors by Product Report - Aug 4, 2007 E2007 (AMPA Receptor Antagonist); Ontak (Denileukin Diftitox); Targretin Capsules (Bexarotene); Targretin Gel (Bexarotene) ... $75.00 - Revere Reports - Revere Competitors by Product Report - Aug 2, 2008 Eisai Co., Ltd (ADR) (ESALY) Products:. E6201 (Multikinase Inhibitor); Ontak (Denileukin Diftitox); Targretin Capsules (Bexarotene) ... $75.00 - Revere Reports - Revere Press Release: Interim HIV Vaccine Trial Results to be Presented at... - Aug 30, 2005 Article: Clinical Trial Results of Targretin(R) Gel in ... Business Wire; May 9, 2000 ; 700+ words ... ... of Medicine, Northwestern University Medical ... Pay-Per-View - PR Newswire - HighBeam Research Competitors by Product Report - Oct 27, 2007 E2007 (AMPA Receptor Antagonist); Ontak (Denileukin Diftitox); Targretin Capsules (Bexarotene); Targretin Gel (Bexarotene) ... $75.00 - Revere Reports - Revere Centron: organic growth continued to fuel revenue for this relatively... - Jul 1, 2008 New wins included Eisai (Ontak, Targretin Capsules and Targretin Gel, plus corporate work assigned in 2008); Velcade from Millennium Pharmaceuticals; ... Pay-Per-View - Medical Marketing & Media - HighBeam Research Article: John Higgins.(Newsmakers)(Ligand Pharmaceuticals Inc.... - Feb 19, 2007 An FDA panel agrees that Targretin should be used for treating patients with cutaneous T-cell lymphoma. Ligand Pharmaceuticals Inc. is the developer of the ... Pay-Per-View - Chain Drug Review - HighBeam Research Ligand Announces Financial Results for Second Quarter of Fiscal 2006;... - Aug 9, 2006 Sales of Targretin capsules increased to $5.0 million (up 6%) and $10.0 million (up ... Targretin capsules sales for the three and six months ended June 30, ... $4.95 - Business Wire - ECNext Minimizing Side-Effects of Oral Bexarotene in Cutaneous T-cell … - Aug 8, 2006 Bexarotene (Targretin®; Ligand Pharmaceuticals Inc., San Diego, CA, ... Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the ... Medscape Ligand's 1st-qtr 2006 revenues up 38%.(Brief article) - May 29, 2006 The firm added that this decline was in line with its spending plan for Phase III trials of Targretin as a treatment for non-small cell lung cancer. Free with registration - Pharma Marketletter - AccessMyLibrary.com Eisai Acquires Four Oncology-Related Products from Ligand. - Sep 8, 2006 ONTAK (denileukin diftitox), Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1% and Panretin (alitretinoin) gel 0.1%. ... Free with registration - JCNN News Summaries - AccessMyLibrary.com Ligand Sells More Products: $205M For Cancer Portfolio - Sep 11, 2006 The agreement with Eisai involves Ontak (denileukin diftitox), for cutaneous T-cell lymphoma; Targretin (bexarotene) gel and capsules, also for CTCL; ... BioWorld Online - BioWorld Online Event Brief of Ligand Pharmaceuticals Earnings and Business Update - ... - Nov 18, 2005 PK saw a nice growth of ONTAK and consistent growth with Targretin capsules. 3. Product GM: 1. The product GMs are somewhat of an anomaly. 1. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Eisai to Acquire Global Rights to Four Oncology-Related Products from... - Sep 8, 2006 ...(Nasdaq: LGND) for exclusive global rights for their four oncology-related products, ONTAK, Targretin capsules, Targretin gel 1% and Panretin gel 0.1%. ... StreetInsider.com - StreetInsider.com (subscription) Avinza acquisition.(RXs)(Brief article) | Article from Chain Drug... - Mar 19, 2007 An FDA panel agrees that Targretin should be used for treating patients with cutaneous T-cell lymphoma. Ligand Pharmaceuticals Inc. is the developer of the ... Pay-Per-View - Chain Drug Review - HighBeam Research Merger and Acquisition Scenario - Jan 27, 2007 Pharmaceuticals: ONTAK (denileukin diftitox), Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1% and Panretin (alitretinoin) gel 0.1%. ... $250.00 - Revere Reports - Revere Ligand Pharmaceuticals Receives Leadership Award from Frost & … - Jan 3, 2005 To date, this has led to five products: Ligand markets four oncology and dermatology products in the United States - ONTAK(R), Targretin(R) capsules, ... $4.95 - Business Wire - ECNext FDA COMMITTEE TO CONSIDER NAVY'S RESUS TRAUMA TRIAL. | … - Jul 1, 2006 ..."We are extremely pleased with the FDA decision to rapidly approve Targretin capsules ... the approval of Targretin capsules by the FDA, ... Pay-Per-View - Biotech Business - HighBeam Research Press Release: Eisai Announces Completion of Acquisition of Four … - Oct 26, 2006 In the agreement, Eisai Co., Ltd. and Eisai Inc. obtained exclusive global rights to ONTAK(R) (denileukin diftitox), Targretin(R) (bexarotene) capsules, ... Pay-Per-View - PR Newswire - HighBeam Research Eisai Acquires Four Oncology-Related Products From Ligand. - Sep 7, 2006 ...rights for ONTAK(R) (denileukin diftitox), Targretin(R) (bexarotene) capsules, Targretin(R) (bexarotene) gel 1% and Panretin(R) (alitretinoin) gel 0.1%. ... $4.95 - PR Newswire - ECNext Competitors by Product Report - Sep 30, 2006 Ligand Pharmaceuticals Inc. (LGND) Products:. Ontak (Denileukin Diftitox); Targretin Capsules (Bexarotene); Targretin Gel (Bexarotene) ... $75.00 - Revere Reports - Revere Article: Data collected on CTCL in children.(Clinical Rounds) - Skin... - Nov 1, 2006 Article: Targretin Capsules Benefit Patients in Treating Refractory ... ... Article: Targretin Gel Achieved 86% Response Rate in Early-Stage ... ... Pay-Per-View - Skin & Allergy News - HighBeam Research Merger and Acquisition Scenario - Dec 16, 2006 Pharmaceuticals: ONTAK (denileukin diftitox), Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1% and Panretin (alitretinoin) gel 0.1%. ... $250.00 - Revere Reports - Revere Factiva Search - Mar 29, 2005 LIGAND'S TARGRETIN FAILS TO IMPROVE SURVIVAL IN NSCLC.(non-small- cell lung cancer). 29 March, 2005 BIOWORLD Today. Boggs, Jennifer ... Pay-Per-View - BIOWORLD Today - Factiva, from Dow Jones Press Release: Eisai Acquires Four Oncology-Related Products From … - Sep 7, 2006 ...rights for ONTAK(R) (denileukin diftitox), Targretin(R) (bexarotene) capsules, Targretin(R) (bexarotene) gel 1% and Panretin(R) (alitretinoin) gel 0.1%. ... Pay-Per-View - PR Newswire - HighBeam Research Merger and Acquisition Scenario - Dec 16, 2006 Pharmaceuticals: ONTAK (denileukin diftitox), Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1% and Panretin (alitretinoin) gel 0.1%. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 25, 2006 Pharmaceuticals: ONTAK (denileukin diftitox), Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1% and Panretin (alitretinoin) gel 0.1%. ... $250.00 - Revere Reports - Revere The Biotechnology Industry Organizations (BIO): Carl Feldbaum, … - Jan 3, 2005 Targretin, initially approved for cutaneous T-cell lymphoma, has achieved clinical results that support combination use with Iressa in non-small-cell lung ... $9.94 - Chain Drug Review - Alacra Store O/E Learning Inc acquires FamilyCare from CareGuide - Deal Snapshot -... - Jan 31, 2006 Its product portfolio includes…results and results from tw o studies of Targretin gel and…first of two pivotal Phas e III studies of Targretin (bexarotene… ... Pay-Per-View - deals - Alacra Store Eisai; Recent developments announced by Eisai - Dec 5, 2006 ...global rights for Ontak (denileukin diftitox), Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1% and Panretin (alitretinoin) gel 0.1%. ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Deep cuts at Ligand.(Ligand Pharmaceuticals Inc. Job cuts and … - Feb 5, 2007 In June, Ligand filed for a new drug application for Targretin . ... Provided the FDA approves Targretin gel, Ligand will have four approved treatments for ... Pay-Per-View - San Diego Business Journal - HighBeam Research Seven Big Investors to Buy Sungard - Mar 28, 2005 Ligand Pharmaceuticals (LGND ) says its two pivotal Phase III studies of Targretin capsules in front-line combination therapy with standard chemotherapy to ... BusinessWeek A brief primer on treatments of cutaneous T cell lymphoma, newly … - Jul 1, 2007 Bexarotene (Targretin[R], Ligand Pharmaceuticals Inc) is a synthetic retinoid analog with a specific affinity for the retinoid X receptor and belongs to a ... $4.95 - Journal of Drugs in Dermatology - ECNext Article: Vic: New drugs could stop fat cell growth, scientists say -... - Oct 29, 2008 Article: Ligand Presents at ENDO '99: Targretin Causes Complete Regression ... Business Wire; June 14, 1999 ; 700+ words ... ... demonstrate that Targretin ... Pay-Per-View - AAP General News - HighBeam Research Ligand Pharma: Günstiges "Lotterieticket" - Jan 14, 2005 Die Ergebnisse einer laufenden klinischen Studie des Lungenkrebsmedikaments Targretin seien im März zu erwarten, so die Analysten. ... FinanzNachrichten.de Health Stocks in Motion - Mar 28, 2005 Ligand Pharmaceuticals (LGND - commentary - Cramer's Take) fell 28.6% after the company said its lung cancer drug, Targretin, failed to significantly extend ... TheStreet.com - TheStreet.com (subscription) Press Release: FDA Approves ASMANEX(R) a New Option for the 20 … - Mar 31, 2005 Article: Ligand's Targretin(TM) (LGD1069) Published in 'Cancer Research' ... PR Newswire; December 16, 1996 ; 700+ words ...RXR-selective compound equally ... Pay-Per-View - PR Newswire - HighBeam Research Pediatric alopecia areata severity should guide Tx; physician... - Jun 1, 2005 Article: T-Cell activation key to targretin gel efficacy: the rexinoid is ... Skin & Allergy News; April 1, 2006 ; 700+ words . ... Pay-Per-View - Skin & Allergy News - HighBeam Research Derm Dx.(Skin Disorders)(B-cell lymphoma) | Article from Family... - Apr 1, 2006 Article: FDA Approves Targretin for Treatment of CTCL. ... Oral Targretin (bexarotene) was approved by the Food ... for use in early- as well as late-stage ... Pay-Per-View - Family Practice News - HighBeam Research Article: Taxol Doesn't Treat Common Breast Cancer - AP Online | … - Oct 10, 2007 Article: Ligand's Targretin Combined With Taxol Prevents and ... ... In this study ... the Targretin / Taxol combination resulted ... ... Pay-Per-View - Associated Press/AP Online - HighBeam Research Article: Taxol Doesn't Treat Common Breast Cancer - AP Online | … - Oct 10, 2007 Article: Ligand's Targretin Combined With Taxol Prevents and ... ... In this study ... the Targretin / Taxol combination resulted ... ... Pay-Per-View - Associated Press/AP Online - HighBeam Research Article: Tool Theft Protection System.(NEW PRODUCTS) - Electrical … - Mar 1, 2006 Article: T-Cell activation key to targretin gel efficacy: . ... And all four appear to respond to bexarotene gel (Targretin), Dr. Marie-France Demierre said ... Pay-Per-View - Electrical Contracting Products - HighBeam Research second-generation | Definition of second-generation | HighBeam.com: … - Jul 12, 2006 Article: FDA Approves Ligand's Targretin Capsules for Early and ... Business Wire; December 29, 1999 ; 700+ words ... ... the treatment of these early- and ... Pay-Per-View - Oxford American College Dictionary - HighBeam Research Article: Taxol Doesn't Treat Common Breast Cancer - AP Online | … - Oct 10, 2007 Article: Ligand's Targretin Combined With Taxol Prevents and ... ... In this study ... the Targretin / Taxol combination resulted ... ... Pay-Per-View - Associated Press/AP Online - HighBeam Research Pharmaceutical firms mix and match to hone pipelines - Mar 3, 2006 Among the 12 products marketed by Zeneus in Europe are Myocet, a cardio-protective chemotherapy agent used to treat late-stage breast cancer, and Targretin, ... Bizjournals.com Lessons from the lung for targeted anticancer drugs - Aug 2, 2007 ...trials (erlotinib, sorafenib [Nexavar; Onyx/Bayer], vandetanib [Zactima; AstraZeneca] or a combination of erlotinib plus bexarotene [Targretin; Eisai]). ... Nature.com St. Paul Pioneer Press : MANY MEDS DON'T MIX WITH THE SUN - Sep 21, 2005 Anti-cancer agents: Bexaro-tene (Targretin), capecitabine (Xeloda), dacarbazine (DTIC), epirubicin (Ellence), fluorou-racil (5-FU), interferon alfa (Intron ... $2.95 - St. Paul Pioneer Press - NewsBank Brand Names/Synonyms: Targretin is also known by the following brand names and/or synonymsBexarotene; Bexarotene [Usan]; LG 1069; LG 69; LGD 1069; LGD1096; Targret; Targretin; Targretyn; Targrexin Drug Category: Targretin is categorized under the following by the FDA: Anticarcinogenic Agents; ATC:L01XX25 Dosage Forms: Not Available Absorption: Not Available Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: 4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoicacid |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |